1-5 of 5
Martin J.S. Dyer, MA, DPhil, FRCP
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5344.
https://doi.org/10.1182/blood-2018-99-113115
Published: 2018
Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 5345.
https://doi.org/10.1182/blood-2018-99-113117
Published: 2018
Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3135.
https://doi.org/10.1182/blood-2018-99-113111
Published: 2018
Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Anders Osterborg, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, Stephan Stilgenbauer, Dr.med, Catherine D Williams, MBBS, MRCP, FRCPath, Andrzej Hellmen, MD, PhD, Tadeusz Robak, MD, PhD, Richard R Furman, MD, Peter Hillmen, MBChB, PhD, Marek Trneny, MD, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Swaminathan Padmanabhan, MD, MBBS, Tomas Kozak, MD, PhD, Geoffrey Chan, MD, Randy L Davis, DrPH, Nedjad Losic, MSc, Charlotte A. Russell, MD, DMSC, Magdalena Piotrowska, MD, Joris Wilms, MSc., Pharm, William G. Wierda, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 328.
https://doi.org/10.1182/blood.V112.11.328.328
Published: 2008
Journal Articles

Protein Profiling of Plasma Membranes and Lipid Rafts Defines Aberrant Signaling Pathways in Mantle Cell Lymphoma

Robert S Boyd, PhD, Rebekah Jukes-Jones, PhD, Renata Walewska, FRCP, David Brown, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Kelvin Cain, PhD
Journal: Blood
Blood (2008) 112 (11): 374.
https://doi.org/10.1182/blood.V112.11.374.374
Published: 2008